Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics

Drug Profile

Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University School of Medicine
  • Class Antineoplastics; Oxazoles; Small molecules; Thiazoles
  • Mechanism of Action Beta catenin inhibitors; Transcription factor inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Mar 2016 Early research in Cancer in USA (unspecified route)
  • 16 Mar 2016 ibeCa Therapeutics acquires worldwide license to develop beta-catenin responsive transcription inhibitors from New York University School of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top